InfuSystem (NYSE:INFU) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of InfuSystem (NYSE:INFU) from a buy rating to a strong-buy rating in a research note issued to investors on Friday.

InfuSystem Price Performance

INFU stock opened at $5.55 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.59 and a current ratio of 1.98. InfuSystem has a 52 week low of $5.28 and a 52 week high of $9.97. The firm’s fifty day moving average is $7.65 and its 200 day moving average is $7.57. The firm has a market cap of $116.60 million, a P/E ratio of 92.52 and a beta of 1.75.

Institutional Investors Weigh In On InfuSystem

A number of large investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its holdings in InfuSystem by 66.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 4,076 shares of the company’s stock worth $27,000 after acquiring an additional 1,626 shares during the last quarter. Barclays PLC grew its holdings in InfuSystem by 10.1% in the 4th quarter. Barclays PLC now owns 31,479 shares of the company’s stock worth $266,000 after acquiring an additional 2,882 shares during the last quarter. State Street Corp grew its holdings in InfuSystem by 1.1% in the 3rd quarter. State Street Corp now owns 267,012 shares of the company’s stock worth $1,789,000 after acquiring an additional 3,019 shares during the last quarter. Wells Fargo & Company MN grew its holdings in InfuSystem by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 9,286 shares of the company’s stock worth $78,000 after acquiring an additional 3,165 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in InfuSystem by 6.3% in the 4th quarter. Millennium Management LLC now owns 76,419 shares of the company’s stock worth $646,000 after acquiring an additional 4,532 shares during the last quarter. Institutional investors own 71.13% of the company’s stock.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.